Olema Pharmaceuticals, Inc.
OLMA$454M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSAN FRANCISCO122 employees
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Jun 30, 2026
15wMarket Overview
Stock performance and key metrics
OLMA News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Palazestrant
Breast Cancer
Ribociclib
Breast Cancer
OP-1250
Hormone Receptor Positive Breast Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Palazestrant | Phase 3 | Breast Cancer | - | - |
Ribociclib | Phase 3 | Breast Cancer | - | - |
OP-1250 | Phase 2 | Hormone Receptor Positive Breast Carcinoma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply